Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Core Viewpoint - The company is preparing to discuss the results of a trial, emphasizing the importance of the press release available on their Investor Relations website [2] Group 1 - The call will include prepared remarks from management followed by a Q&A session [2] - The company highlights that remarks regarding future expectations are forward-looking statements protected under the Private Securities Litigation Reform Act of 1995 [2] - The company cautions that these forward-looking statements are subject to risks and uncertainties that could lead to actual results differing materially from expectations [2]